Drugs / BBI-355
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05827614 | Mar 2023 → Mar 2026 | cervical squamous cell carcinoma, endometrial carcinoma, estrogen-receptor positive breast cancer, head and neck squamous cell carcinoma +7 | Boundless Bio, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Boundless Bio, Inc. | Results Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 boundlessbio.com ↗
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBI-355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05827614 ↗ |
| Action | Inhibit | “Oral CHK1 inhibitor” NCT05827614 ↗ |
| Modality | Small molecule | “BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development” NCT05827614 ↗ |
| Route | Oral | “Single agent BBI-355, administered orally in 28-day cycles” NCT05827614 ↗ |